Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat Versus Hydroxyurea in High-risk Polycythemia Vera
NCT06093672Phase 3Recruiting
- Sponsor
- Italfarmaco
- Start
- Mar 2024
- Primary completion
- Jul 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of givinostat in polycythemia vera (PV) (2 arms), sponsored by Italfarmaco. Primary endpoint: Proportion of patients achieving a response at Week 48. Started Mar 2024; status: recruiting.
02
Drugs
givinostat
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06093672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093672.